Material
T
here is a growing consensus that an effective HIV vaccine should include a component that elicits broadly neutralizing Abs (bNAbs; reviewed in Refs. [1] [2] [3] [4] [5] . A growing number of bNAbs have been identified and characterized (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Several bNAbs have been shown to afford protection in passive transfer studies in animals (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . However, eliciting significant levels of bNAbs through immunization has not yet been successful. B cells producing bNAbs may not be efficiently generated for several reasons. Precursor HIV envelope (Env)-specific B cells may be rare because of immune tolerance (29) or because cells of the appropriate specificity are difficult to generate through the processes of gene diversification. For example, some bNAbs appear to require relatively unusual structures, such as very long H chain CDR3s (6, 12) or domain exchange (30) . Alternatively, bNAb precursor B cells may be abundant but difficult to stimulate owing to topological reasons, for example, because the epitope has poor accessibility, or because of the need for more powerful adjuvants or immunogens of a more stimulatory nature.
To elicit a bNAb response to HIV-1 Env, B cells with bNAb specificities must be activated. In this study, we have expressed in B cell lines a number of previously identified broadly neutralizing HIV Abs that recognize a variety of sites on Env, including the CD4 binding site (b12, VRC01, PGV04, PGV19, NIH45-46), the membrane-proximal external region of gp41 (4E10), a V2/glycandependent site on the trimer (PG9, PG16, PGT145), the highmannose-rich face of gp120 (2G12), a V3/glycan site (PGT128), a V4/glycan site (PGT135), and another glycan-dependent site still being defined (PGT121). We then tested the ability of different Env-containing Ags and virions to stimulate these cells. The results suggest that soluble Env trimer preparations are highly stimulatory for early calcium mobilization, whereas monomers and virion preparations, including infectious virions and pseudovirions, are generally nonstimulatory. However, internally labeled pseudovirions were shown to bind to mutated, but not germlinereverted bNAb (gl-bNAb)-expressing B cells and to stimulate the expression of the early activation marker CD69 upon prolonged exposure in vitro. These findings suggest that naturally expressed HIV-1 Env glycoprotein is poorly stimulatory for bNAb-expressing B cells and that soluble trimers or multimeric scaffolded epitopes capable of binding gl-bNAbs may be more desirable components for an effective HIV-1 vaccine that elicits bNAbs.
Materials and Methods

Conventional B cell transfectants
For the H chain gene constructs, the mouse V H J558.85.191 promoter and leader were fused to the b12 or 2G12 VDJ exon, yielding an Asc1-flanked *Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037; † promoter-L-VDJ segment, which was then extended to include the intronic enhancer using sequences from the natural interval starting from the end of mouse J H 4 to the downstream EcoR1 site. An EcoR1 fragment carrying this construct, including splice donor sequences, was cloned into the EcoRI site in the pSal genomic IgM expression vector. pSal is a modified version of the plasmid 3-83m (34) in which an irrelevant EcoR1 site was changed to Sal1 and the EcoR1 fragment carrying the natural VDJ was removed. For constitutively expressed L chain constructs, VJ sequences were appended on the 59 end with a leader sequence from Vk4-53 or the mouse IgG1 signal sequence and at the 39 end with hCk cDNA (modified from a vector received as a gift from Patrick Wilson, University of Chicago). Coding sequences were inserted into the pBudCE4.1 expression plasmid (Invitrogen, Carlsbad, CA), which drives expression under the EF-1a promoter. The V(D)J sequences of b12 and 2G12 were previously described (35, 36) . Electroporation of K46 mouse B cells was carried out as follows: 10 mg both H and L chain expression vectors (linearized using SalI and NheI, respectively) was added to 5 3 10 6 K46 cells in 500 ml DMEM and incubated in 4 mm cuvettes on ice for 5 min. Cells were subjected to electroporation with a Gene Pulser Xcell (Bio-Rad, Hercules, CA), set at 230 V, 960 mF, and ' V resulting in a time constant of ∼30 ms. After incubation on ice for 10 min cells were cultured in 24-well plates with complete medium (DMEM or RPMI 1640, 10% FCS, 55 mM 2-ME, 2 mM L-glutamine, 100 mg/ml streptomycin, 100 IU/ml penicillin, 100 mM nonessential amino acids). Selection was started after 0-2 d with 1 mg/ml G418 (Life Technologies, Carlsbad, CA) for H chain transfections and/or 1 mg/ml Zeocin (Invitrogen) for L chain transfections. Surviving cells were passaged as needed. After selection, single clones were generated by single cell sorting of H and/or L chain-expressing K46 cells on a FACSAria (BD Biosciences, San Jose, CA).
B cell lines transduced with lentivirus-encoded Ab constructs
bNAb V region-containing cDNA plasmids were used as templates for PCR sewing using appropriate primers. bNAb LVDJ elements were linked with mouse IgM C region cDNA sequence, and then the resulting m H chain gene was further linked with a Gly-Ser-Gly linker followed by the P2A peptide and the mature L chain sequences, which carry human Ck or Cl constant regions corresponding to the original L chain used. PG9, PG16, PGV19, PGT121, and PGT128 carry l L chain, whereas the other bNAbs use k. Fusion genes with the corresponding restriction sites were cloned into EcoRI/NotI digested modified gateway entry vector (Invitrogen) and then transferred to pLenti CMVTRE3G Puro Dest plasmid (developed by Eric Campeau and obtained from Addgene) using the LR Clonase II enzyme (Invitrogen). bNAb-encoding lentiviruses were produced as previously described (37) . Briefly, each bNAb TRE3G plasmid was cotransfected with psPax2 and MD2.G plasmids into 293T cells using FuGENE HD. Cell supernatants harvested on day 2 were used to transduce rtTA3G-expressing WEHI-231 or K46 B cell lines in the presence of 10 mg/ml polybrene (Millipore). Starting 2 d later, cells were selected with 2 mg/ml puromycin. bNAb-expressing cells were induced by incubation with doxycycline (1 mg/ml) overnight and stained with 200-fold diluted anti-hCk-biotin (G20-193; BD Biosciences) or hCl-biotin (JDC-12; BD Biosciences) in FACS buffer and further stained with streptavidin-PE (eBioscience). Highexpressing cells were selected by sorting using a FACSAria II (BD Biosciences) or MoFlo (Beckman Coulter) machines. Single clones of some cell lines were obtained by limiting dilution. Anti-CD69-allophycocyanin (H1.2F3) was purchased from eBioscience. mAbs against mouse IgM (M41; DyLight 650) were labeled in-house. All samples were read on an LSR II instrument (BD Biosciences) and analyzed using the FlowJo program (Tree Star, Ashland, OR).
Generation of HIV virions
HIV-1 enveloped pseudoviruses were prepared by cotransfecting 293T cells with 15 mg backbone plasmid (pSG3ΔEnv or pNL4-3.Luc), 5 mg functional wild-type or b12-knockout mutant (D185A, P369Q) envelope clone, and FuGENE reagent (Roche) as previously described (38, 39) . Green fluorescent viruses were prepared by cotransfection of pEGFP-C3 (Clontech, Madison, WI) containing the entire Vpr coding region fused to the COOH terminus of enhanced GFP (EGFP; GFP-Vpr) (40) . Virus stocks were titrated on TZM-bl cells as described (38, 39) and the 50% tissue culture-infective doses were calculated according to Reed and Muench (41) . The p24 concentration was determined by ELISA (Aalto Bio Reagents, Dublin, Ireland; do-it-yourself ELISA protocol 2).
Envelope protein concentration
Concentrated JRFLDCT-GFP virus was tested by ELISA for Env protein amount as follows. A 1000-fold concentrated JRFLDCT virus was first diluted in TBS, 1% Empigen BB (Sigma-Aldrich), 1% BSA, and 0.1% Tween 20 and then serially diluted in TBS 1% BSA and 0.1% Tween 20 and applied to ELISA plates (Nunc MaxiSorp) previously coated with sheep anti-gp120 (Aalto Bio Reagents) at 3 mg/ml. JRFL gp140 trimer was used as standard. Bound envelope protein was detected with PGT121, followed by detection with biotinylated anti-human lambda (BD Biosciences) and streptavidin-HRP (BD Biosciences). This approach revealed that 1000-fold concentrated JRFLDCT virus stock contained 11.2 nM (4.7 mg/ml) Env trimer equivalents.
Flow cytometry
Binding of biotinylated Ags or Abs to B cell lines was measured on a C6 flow cytometer (Accuri, Ann Arbor, MI) or LSR II (BD Biosciences) either using directly labeled Abs (anti-mouse Igm [M41], anti-human kappa; Jackson ImmunoResearch Laboratories) or using biotinylated Ags (biotingp120 JRFL/JRCSF/YU2) and a streptavidin-PE secondary probe. Abs used for detection of activation markers for K46 cell stimulations included IgM (M41) Alexa 488 or 647, CD69 (H1.2F3), CD83 (Michel-19), and CD19 (6D5). Abs, except IgM (M41), were purchased from BioLegend (San Diego, CA). Sheep anti-HIV-1 gp120 (Aalto Bio Reagents) was labeled with Alexa Fluor 647 (Life Technologies, Grand Island, NY) depleted for cross-reactivity against K46 b12-and 2G12-expressing K46 cells for 25 min at room temperature and filtered for detection of HIV proteins bound to the cells surface by flow cytometry. The His-tag mAb used in crosslinking and detection of the 2bodx-043 b12 scaffold was purchased from GenScript (Piscataway, NJ). FlowJo (Tree Star) and Prism 5.0 for Mac (GraphPad Software, La Jolla, CA) were used for analysis.
Ca
2+ flux assays
In all experiments, except for those shown in 
HIV Ags
YU2 gp120-His 6 AviTag was cloned into pIRES-hrGFP Zeocin plasmid and cotransfected with BirA-ER plasmid to 293F cells. Stable drugresistant cells were obtained and cultured in 5% FCS containing Advanced DMEM (Invitrogen), penicillin, streptomycin, Glu-Max, and 0.2 mM biotin. Expressed protein was purified over HisPur cobalt resin (Thermo Scientific), eluted with imidazole, and dialyzed against PBS. YU2 gp120 biotinylation was confirmed by Western blot using HRP antibiotin Ab (Jackson ImmunoResearch Laboratories). YU2 gp140-GCN4-bio and JRFL trimers were prepared as described (42, 43) . 92BR020 gp120 monomer sequences were cloned into the phCMV vector and the plasmid was used to transfect 293F cells. The gp120 protein was purified from supernatants by Galanthus nivalis lectin chromatography followed by size exclusion chromatography. The 293F cells were grown in 293F expression media (Invitrogen).
Results
Conventional B cell transfectants carrying b12 or 2G12
In initial experiments, we expressed H and L chains of b12 and 2G12 in the B cell line K46 using mouse genomic constructs encoding H chains carrying IgM constant (C) regions and pEF1a-driven cDNA plasmids for the L chains, which carried human Ck. Coexpression of the desired Ig chains was verified by detection of Abs to human Ck and to IgM (Fig. 1A , lower panels). As controls, we also included untransfected K46 cells and a K46 transfectant (K46J) expressing the IgM Ab 3-83 (44, 45) (Fig. 1A, upper panels) . B cell lines coexpressing IgM H chain and human Ck were obtained (Fig. 1A) , indicating that they carried high levels of the desired Abs. To assess specificity, we measured the binding of gp120 monomers to the cells and detected binding specifically to b12-and 2G12-expressing cells. We were also able to detect binding by the cells to YU2 gp140 and JRFL gp140 trimer preparations (Fig. 1B and data not shown) (43) . The fine specificity of b12 cells for gp120 was further confirmed by their inability to react with the CD4 binding site mutant YU2 D368R (46) (Fig. 1B , middle panel). In contrast, 2G12, which binds to a distinct site on gp120, bound both mutant and wild-type versions similarly (Fig. 1B , lower panel). Binding of JRFL gp120 monomer by b12 cells was detected using as little as 0.26 nM (31 ng/ml) Ag (Fig. 1C ). These data show that one can generate B cell lines expressing bNAbs as a BCR, providing a new tool to assess vaccine candidate Ags for their ability to stimulate anti-HIV B cells.
Ca 2+ flux analysis
To measure Ag-driven cellular activation, we stimulated B cell lines expressing or lacking anti-HIV BCRs with various Env proteins, protein scaffolds carrying selected epitopes, or virion preparations and we monitored increases in intracellular Ca 2+ levels ( Fig. 1D-I ). We found that Ca 2+ responses in b12 or 2G12 cells could be stimulated only with multimeric gp120 preparations. Env monomer preparations were nonstimulatory unless they were multimerized on the surface of avidin-carrying liposomes, whereas soluble gp140 trimers, generated using heterologous C-terminal foldon trimerization motifs, gave robust stimulation for b12-expressing cells ( Fig  1D) . Trimers also triggered 2G12 cells, but required higher concentrations (not shown). Activation was strictly specific for Ag, as YU2 trimers carrying the D368R CD4-binding site mutation, which abrogates b12 binding and neutralization, were unable to activate b12 cells (Fig. 1E ). Anti-IgM was used in these experiments as a positive control. Env preparations that were stimulatory for two independently generated clones of b12 cells (b12-1 and b12-2) failed to activate control K46J cells, which carry an irrelevant surface IgM (Fig. 1F) . Soluble trimers generated using gp140 expression constructs were able to stimulate b12 cells at concentrations as low as 0.5 nM (Fig. 1G) . We also found that the b12 epitope scaffold 2bodx-043 (47) was stimulatory provided that it was presented in a multimeric form (Fig. 1H) . Thus, soluble multimeric Env proteins or their mimics are stimulatory for these bNAb-expressing cell lines.
Having established the ability of the B cell lines coexpressing HIVAbs to be stimulated by various soluble HIV Env preparations, we next assessed their ability to recognize pseudovirions (JRCSF, JRFL, BaL, SF162) or virions (NL4-3) carrying distinct, wellcharacterized Env. These viruses were chosen because of their known sensitivity to neutralization by the Abs in question. These infection-competent preparations failed to promote a Ca 2+ flux. Fig. 1I shows that freshly prepared JRFL pseudovirus was inactive, in contrast to gp140 trimer, in triggering a Ca 2+ flux. Similar negative results were obtained when we tested the DCT mutant version of JRFL, which is predicted to carry ∼5-to 10-fold higherthan-normal levels of surface envelope proteins (48) (Supplemental Fig. 1A) . The highest doses of pseudovirions corresponded to a multiplicity of virions to cells of ∼10 4 . We verified that the pseudovirions tested carried native, functional Env because they could infect target cells. Collectively, these data indicated that live, functional viruses or pseudoviruses could not appreciably stimulate K46 B cells carrying 2G12 or b12. These results suggest that, in many cases, virions carrying Env proteins capable of being neutralized by free b12 or 2G12 Abs fail to stimulate B cell lines carrying these same Abs as BCRs.
These results led us to wonder whether virus preparations might inhibit B cell activation. We first tested whether free monomers could suppress the activation induced by soluble trimers. Indeed, high levels of monomer led to an appreciable loss of Ca 2+ flux in response to soluble trimer (Supplemental Fig. 1B) , presumably by simple competition. In contrast, pseudovirions were unable to suppress the response to soluble trimers (Supplemental Fig. 1C) . Hence, the inability of pseudovirions to stimulate B cell lines carrying bNAb BCRs could not be attributed to contamination with nonstimulatory Ag forms or to an independent inhibitory activity of virions.
Generation of B cell lines carrying P2A-linked and inducible anti-HIV BCRs
During the course of the above-mentioned studies we attempted to generate stable B cell lines carrying a number of other broadly neutralizing HIV Abs. However, we had some difficulties in doing so, in part because of the inefficiency of conventional electroporation methods, and possibly also because their expression was toxic to the cells, perhaps because of BCR autoreactivity. To facilitate expression, we engineered Ab cDNAs into lentivirus vectors that drove expression of both H and L genes from a single cistron separated by the picornavirus 2A peptide. The 22-residue 2A peptide prevents the formation of a normal peptide bond between glycine and the last proline, effectively "cleaving" the peptide in two during translation ( Fig. 2A) . This allows one to express Ig H and L chains at an equal molar ratio using just one compact gene. In this case, we used C region sequences from the membrane form of mouse m H chain and human k or l L chain. Although initial experiments were done using lentivirus vectors driving bNAb constitutive expression, we show in these studies using doxycycline-inducible bNAb expression in WEHI-231 and K46 B cells expressing the Tet transactivator rtTA3G (Fig. 2 and Supplemental Fig. 2, respectively) . WEHI-231 cell lines expressing several bNAb BCRs (Table I) were assessed by flow cytometry for the ability to bind to cognate Ag and for levels of human k or l L chains (Fig. 2B-E) . Based on the expression of one Ab chain or another, all 16 tested bNAb specificities were expressed. Because the constructs encoded both chains off one cistron, it is assumed that lentivirus-encoded H and L chain protein expression levels were similar. Importantly, transductants of most bNAbs exhibited demonstrable binding to soluble Env proteins ( Fig. 2B-E) . In contrast, however, cell lines expressing germline-reverted (given prefix "gl") versions of 4E10, b12, and VRC01 (sequences given in Table II) , exhibited high-level surface expression of both transduced chains, but they failed to bind soluble Env proteins (Fig. 2D, 2E and data not shown). This indicated that the receptors were expressed but had too low of an affinity to detectably bind to soluble Ag. We conclude that the induced expression of transduced bNAb BCRs was generally achieved, but that gl-bNAb receptors bound Ag poorly despite high level expression.
Binding and activation by ligands in cells with inducible bNAb BCRs
In these cell lines, bNAb expression was strictly doxycyclinedependent and readily induced upon overnight incubation with 1 mg/ml drug (Fig. 3A) , allowing us to use uninduced cells as negative controls for binding and activation studies. Accordingly, cells carrying or lacking VRC01, PGT121, or b12 BCRs were compared for their abilities to bind and to be activated by BCR ligands, soluble Ags, and pseudovirions. As with the b12 and 2G12 cell lines described above, we were unable to detect a Ca 2+ mobilization response to pseudovirions, whereas the response to anti-human L chain was robust (Fig. 3B, 3C ). After challenge with pseudovirions, b12 cells were fully able to respond to anti-hCk, again arguing that pseudovirions were not suppressive in this assay (Fig. 3C , BaL/hCk, JRFLDCT/hCk).
We reasoned that the inability of virions or pseudovirions to stimulate B cells could be the result either of an inability of the viruses to bind to the bNAb BCRs or to a failure to trigger upon binding. To address these issues, we assessed the binding of virions by either generating virus particles that incorporate GFP or by detection of bound particles with secondary Abs. In studies using stably transfected K46 cells, we often had difficulty detecting specific binding, as defined by binding that was dependent on the presence of an anti-HIV BCR and could be inhibited by soluble Env protein (data not shown). In contrast, as shown above, binding to soluble monomeric or trimeric Env proteins was readily demonstrable. To extend these experiments, we incubated B cell lines on ice with infectious virus preparations, followed by low-speed centrifugation, to test their ability to absorb infectious activity. These studies failed to demonstrate specific binding to cells carrying anti-HIV BCRs. In contrast, however, use of highly concentrated, internally GFP-labeled pseudovirions derived from JRFLDCT virus allowed clear documentation of BCR-specific binding (Fig. 3D) . Similar results were obtained with the b12 and 2G12 K46 clones described above (data not shown). Under these conditions, however, no Ca 2+ mobilization was seen (Fig.  3B, 3C) . Similar results were obtained with BaL pseudovirions (Fig. 3C, 3D) . We conclude that pseudovirions, and by inference, native viruses, fail to efficiently trigger cognate B cell lines, even those potentially capable of neutralization, and even under conditions where virions are bound. In contrast, soluble trimers and other multimeric presentations of Env can be quite stimulatory.
Analysis of induction of early activation markers
We considered the possibility that virus/B cell interactions or virion-induced activation were too weak or slow to be detected by Ca 2+ flux assays, but they might occur upon extended incubation. To assess this, we took advantage of the fact that B cells upregulate activation markers after 12-24 h BCR signaling. CD83 and CD69 were increased in expression upon anti-BCR stimulation of K46 transfectants (data not shown), whereas in WEHI231 cells, The H chain genes carry a leader exon followed by VDJ codons and C region for membrane IgM. This is followed in frame by the picornavirus P2A peptide, shown below, and the L chain VJ and C codons. Also shown is the puromycin resistance gene (puro). The vertical arrow shows the P2A "cleavage" site, which lacks a peptide bond upon translation. (B-E) Expression and soluble Env binding by the indicated bNAb BCRs in transduced WEHI231 cells. Final concentration of Ags used in staining was 25 mg/ml, except for 98BR020 monomer, which was at 20 mg/ml.
The Journal of ImmunologyCD69 expression alone was well induced. We then assessed the ability of 18 h incubation with virions to induce expression. Although experiments using K46 transfectants were all negative, we were able to observe, in several WEHI231 bNAb transductants, a virion-mediated and BCR-dependent induction of CD69 (Fig.  4A) . Consistent with the soluble trimer binding data of Fig. 2 , cells carrying germline-reverted versions of these bNAbs failed to upregulate CD69 (Fig. 4A) . Interestingly, under these conditions bNAb-expressing cells clearly bound or took up GFP + virions, as they scored GFP + when assessed by flow cytometry (Fig. 4B) , and binding to b12 and VRC01, but not 4E10, was correlated with BCR downmodulation (Fig. 4C) . Stimulation of CD69 expression, hCk downregulation, and binding of BaL or JRFLDCT was dosedependent in b12 WEHI231 cells, but was weak or negative in cells carrying germline-reverted b12 BCR (Fig. 4D-F) . These data indicate that induction of CD69 expression was likely caused by binding of virus particles, rather than shedding of Env trimers, which would lack associated GFP. We conclude that pseudovirions were poorly stimulatory for, but not invisible to, bNAb-expressing B cell lines, possibly owing to degradation in culture or to a slower pace of cell activation.
Discussion
To understand how to generate desired Ab responses eliciting broadly neutralizing HIV Abs, it is important to have models of bNAb-expressing B cells. In this study, we have addressed this goal by introducing bNAbs into B cell lines and assessing their binding and activation by pseudovirions and other predicted bNAb ligands. We find that soluble gp140 trimers are especially efficient at binding and cell activation, whereas gp120 monomers and pseudovirions fail to efficiently activate these cells. Simple multimerization of biotin-tagged gp120 monomers on liposomes carrying avidin restored activation of b12-expressing cells. Activation in this study was measured by assessing rapid Ca 2+ mobilization upon Ag exposure. We also assessed upregulation of surface markers such as CD69 and CD83, when Ag was included in B cell line cultures for 18 h. Infection-competent pseudovirions, which should display Env trimers in a multimeric, albeit paucivalent, array failed to activate obvious Ca 2+ mobilization, but at high concentrations they did bind to bNAb-expressing cells and promoted CD69 upregulation upon prolonged exposure. Importantly, virions at superphysiological concentrations failed to rapidly stimulate even highaffinity B cell lines with bNAb specificity. Based on these in vitro features, our data suggest that soluble trimers (or perhaps higher order soluble multimers) should be most effective as vaccine components in driving B cell activation responses, whereas unmultimerized monomer gp120 and lentivirus-like particles are likely to be less effective. Immunization studies in animals support the notion that trimers may be more efficient for Ab induction than monomers (42, 43, 49). A surprising finding in our studies was the inability of infectioncompetent HIV Env-expressing pseudovirions to activate Ca 2+ responses in anti-HIV B cell lines, even though these cells carried cognate Abs capable of neutralizing the same virus and responding to its Env when presented in soluble trimeric form. This general result was obtained with cell lines carrying bNAb BCRs specific for at least three distinct epitopes on Env: the CD4 binding site (b12, VRC01), the carbohydrate-dependent epitope defined by PGT121, and the high mannose epitope defined by 2G12. These findings, along with the detection of some virus binding to cells, suggest that the BCR had access to Env epitopes on the virus surface, and that virions were available at sufficient concentration, but that these interactions failed to generate the necessary conformational changes or crosslinking required for strong immediate biochemical signal transduction. Alternatively, or additionally, soluble Env trimers might be less conformationally constrained than are virion-bound spikes, which would favor bNAb BCR crosslinking by trimers. Multimeric particulate Ag is typically more stimulatory for B cells than are paucivalent Ags (50, 51), but T cell-dependent Ab responses are not thought to be strictly dependent on Ag multimerization. Cryoelectron microscopy tomography studies have indicated that HIV-1 particles carry on average only 14 spikes, which are widely dispersed (52) . Spike paucivalency might reduce the BCR occupancy possible even at saturating virion concentrations. Note that the concentration of virions used for B cell line stimulations in this study exceeded by several orders of magnitude the virus titers typically seen at the peak of acute HIV infection, and in many experiments we used JRFLDCT pseudovirions, which have an elevated number of spikes. Additionally, similarly constructed bNAb B cell lines reactive to influenza virus responded robustly to those virions even at low virion concentrations (data not shown). Although bNAb B cell lines may be less sensitive to virion Ags than primary B cells, given that even B cell lines carrying high-affinity receptors failed to be well activated by virions, it seems likely that the unhypermutated precursors of bNAb B cells should not be efficiently activated during natural infection. These difficulties perhaps explain why bNAbs typically appear in patients only after years of infection. Initiating the gl-bNAb response might require one or more fortuitous events, such as the appearance during infection of virion variants carrying high epitope densities of Env, along with fortuitous mutations in gl-bNAb B cells (while responding to non-HIV Ags) that allow them to subsequently see HIV.
We considered the possibility that the virions engage inhibitory receptors on B cells to actively suppress triggering. However, this seems unlikely for three reasons. First, we tested, and failed to detect, any inhibitory effect of pseudovirions on Ca 2+ mobilization responses to Env trimers given simultaneously. Second, even the most robust inhibitory signals typically fail to completely prevent a Ca 2+ response, but rather blunt and redirect initial signaling (53, 54) . Finally, incubation of B cells with high concentrations of viruses was able to reveal some activation at 18 h, as indicated by early activation marker expression. We conclude that the low density of Env or an adapted inability to cluster BCRs accounts for the weak stimulatory activity of virions. However, we cannot exclude that virions change conformation or shed soluble multimeric receptors upon cell culture.
Anti-HIV B cell lines could have many practical uses. One is to rank and categorize different HIV Ags and isolates for relevant structural features that affect interactions with responding B cells. This application is nontrivial because the arrangement of the Ag receptor on the B cell membrane involves tight association with the CD79a/b complex and other elements that likely sterically restrict some approaches of the BCR to virions or vaccine candidates. bNAb BCR expression in B cell lines may also facilitate analysis of receptor reactivity to ligands that mimic HIV. For example, we have been able to validate the ability of HIV epitopes engineered into heterologous scaffold proteins to activate cognate B cells. This approach should be most beneficial when used in conjunction with gl-bNAb specificities, which have essentially undetectable affinity for the HIV Ags (this study and Refs. 13, 32, 55, 56, 57) . bNAb B cells might also be helpful in defining conditions to detect B cells with similar specificities in HIV-infected patients. Additionally, bNAb-expressing B cell lines could facilitate analysis of receptor autoreactivity. We have consistently observed that 4E10-transduced B cells poorly express their BCRs, and such cells selectively lose that expression with time in culture, whereas cells carrying distinct BCRs, including germline-reverted 4E10, are quite stable. 4E10 and the anti-membrane-proximal external region mAb 2F5 have been reported to be, at least weakly, self- reactive owing in part to the hydrophobicity of their CDRH3 elements (29, 58) . Consistent with this, mice carrying the 4E10 BCR show clear signs of B cell central tolerance (Colleen DoyleCooper and David Nemazee, manuscript in preparation; Laurent Verkoczy, personal communication). However, our germline-reverted 4E10 BCR that retains CDRH3 sequences appears to be well expressed. PG9, PG16, and VRC01 BCRs also appeared to be selected against in B cell lines, although the significance of this is unclear. In the case of PG9, BCR expression was too low to evaluate responses to Env ligands.
Although self-reactivity may preclude some B cell specificities from contributing to the normal repertoire through tolerance mechanisms, polyreactivity has been argued to contribute to the anti-HIV response by promoting bivalent heteroligation between one high-affinity anti-HIV-gp140 combining site and a second low-affinity site on another molecular structure on HIV (15) . That study evaluated the effects of polyreactivity on the effector phase of the anti-HIV response, but it did not address the induction phase. In this study, B cell lines carrying BCRs with specificity for distinct Env epitopes (b12, VRC01, 2G12, PGT121) failed to mobilize Ca 2+ upon short-term incubation with infectioncompetent pseudovirions, despite the ability of these same BCRs to neutralize the same virus when provided as free Ig, and despite the ability of these BCRs to be triggered by soluble trimers. Binding of bNAb cell lines to pseudovirions, although poor, was detectable by direct flow cytometry analysis and by CD69 upregulation upon overnight cell culture. Thus, Ab polyreactivity might conceivably contribute to late, but not to early, B cell activation. However, it is unclear whether activation induced with extended in vitro incubation is of relevance in vivo in HIV infection because the plasma t 1/2 of virions is remarkably short, on the order of minutes (59) . In any case, the analysis of early activation markers on the bNAb B cell lines provides a readout that may be useful in ranking the potency of candidate vaccine Ags for HIV.
The binding patterns of bNAb B cell lines to soluble Env Ags were not entirely as predicted (9, 12, 14, 16, 60) . As expected, all five CD4 binding site bNAbs along with three glycan-dependent bNAbs (PGT121, PGT128, and PGT135) reacted to both gp120 monomers and trimers. However, PGT145 and PG16 were not expected to bind to soluble YU2 trimers, whereas PG9 has weak affinity (9) . PG9, PG16, and PGT145 are thought to be relatively specific for membrane trimers of YU2 (9), but PG9 and PG16 can see monomers of certain other isolates (12) . PG9 cell lines likely fail to bind trimer owing to poor surface expression or receptor downregulation (Supplemental Fig. 2) . Surprisingly, the PG16 B cell line bound not only soluble YU2 gp120 trimers, but also weakly to YU2 monomer. Because comparable results for PG9, PG16, and PGT145 were obtained in K46 and WEHI231 cell lines transduced with these sequence-verified BCRs (not shown), it is unlikely that the endogenous Ig chains expressed by the cell lines paired with transduced Ig chains to generate novel anti-Env specificities, or that these specificities arose from V region mutations occurring after transduction. One possibility for these discrepancies is that the B cell lines alter bNAb affinity by posttranslational modification. PG9 and PG16 are partially sulfated on CDRH3 tyrosine contact residues, which improves neutralization 10-to 100-fold (10, 12) . These modifications might be distinct in quality or quantity in B cell lines compared with the 293 cells used to generate recombinant Abs for binding studies. Most importantly, however, for vaccine research studies, all gl-bNAb B cell lines tested in the present study failed to bind to, or be activated by, any Ag preparation tested, supporting studies indicating that gl-bNAbs lack detectable affinity for Env Ags (13, 32, 55, 56, 57 ).
Our gl-bNAb B cell lines should be useful in modeling vaccine candidates intended to target gl-bNAb B cells.
We have studied B cells carrying the IgM form of BCR. IgM is thought to extend farther from the plasma membrane than most other Ig classes owing to its additional C H domain, but it lacks a flexible hinge region. It may be that other Ig classes are better adapted to dimerization by Env spikes, or heteroligation to other epitopes. For the purposes of vaccine design, however, the naive B cells that would presumably be targeted initially by any HIV vaccine are likely to express IgM and to lack class-switched isotypes. In this regard, B cell lines carrying the germline versions of several bNAbs will potentially be useful in probing vaccine candidates designed to initiate the bNAb response. Supplemental Figure 2 
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